An integrin β 3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition

Nature Cell Biology

Volumn 16, Issue 5, 2014, Pages 457-468

  Seguin, Laetitia ^a   Kato, Shumei ^b   Franovic, Aleksandra ^a   Camargo, M Fernanda ^a   Lesperance, Jacqueline ^a   Elliott, Kathryn C ^a   Yebra, Mayra ^a   Mielgo, Ainhoa ^a   Lowy, Andrew M ^c   Husain, Hatim ^b   Cascone, Tina ^d   Diao, Lixia ^d   Wang, Jing ^d   Wistuba, Ignacio I ^d   Heymach, John V ^e   Lippman, Scott M ^a   Desgrosellier, Jay S ^a   Anand, Sudarshan ^a   Weis, Sara M ^a   Cheresh, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Division of Surgical Oncology Departments of Surgery San Diego CA 92093   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FOCAL ADHESION KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; PROTEIN RALB; PROTEIN TBK1; TRANSCRIPTION FACTOR REL; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CELL MEMBRANE; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INHIBITION KINETICS; LUNG CANCER; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME; TUMOR XENOGRAFT;

MUS;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; INTEGRIN BETA3; LUNG NEOPLASMS; MICE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PHENOTYPE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-REL; QUINAZOLINES; RAL GTP-BINDING PROTEINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899860489     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb2953     Document Type: Article

References (59)

1. Patel, P. & Chen, E. I. Cancer stem cells, tumor dormancy, and metastasis. Front. Endocrinol. 3, 125 (2012).
2. Hermann, P. C. et al. Distinct populations of cancer stem cells determine tumour growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323 (2007).
3. Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (2005).
4. Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751 (2010).
5. Liu, S. & Wicha, M. S. Targeting breast cancer stem cells. J. Clin. Oncol. 28, 4006-4012 (2010).
6. Magee, J. A., Piskounova, E. & Morrison, S. J. Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer Cell 21, 283-296 (2012).
7. Adhikari, A. S., Agarwal, N. & Iwakuma, T. Metastatic potential of tumour-initiating cells in solid tumours. Front. Biosci. 16, 1927-1938 (2011).
8. Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9-22 (2010).
9. Lo, P. K. et al. CD49f and CD61 identify Her2/neu-induced mammary tumour-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFbeta signaling. Oncogene 31, 2614-2626 (2011).
10. Vaillant, F. et al. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res. 68, 7711-7717 (2008).
11. Visvader, J. E. & Lindeman, G. J. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768 (2008).
12. Miller, P. G. et al. In vivo RNAi screening identifies a leukemia-specific dependence on Integrin Beta 3 signaling. Cancer Cell 24, 45-58 (2013).
13. Desgrosellier, J. S. et al. An integrin α(v)β(3-c-Src) oncogenic unit promotes anchorage-independence and tumour progression. Nat. Med. 15, 1163-1169 (2009).
14. Pecheur, I. et al. Integrin α(v)β3 expression confers on tumour cells a greater propensity to metastasize to bone. FASEB J. 16, 1266-1268 (2002).
15. Knowles, L. M. et al. Integrin αvβ3 and fibronectin upregulate Slug in cancer cells to promote clot invasion and metastasis. Cancer Res. 73, 6175-6184 (2013).
16. Sloan, E. K. et al. Tumour-specific expression of αvβ3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 8, R20 (2006).
17. Hieken, T. J. et al. Beta3 integrin expression in melanoma predicts subsequent metastasis. J. Surgical Res. 63, 169-173 (1996).
18. Workman, P. & Clarke, P. A. Resisting targeted therapy: fifty ways to leave your EGFR. Cancer Cell 19, 437-440 (2011).
19. Ciardiello, F. & Tortora, G. EGFR antagonists in cancer treatment. Engl. J. Med. 358, 1160-1174 (2008).
20. Wheeler, D. L., Dunn, E. F. & Harari, P. M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 7, 493-507 (2010).
21. Engelman, J. A. & Janne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14, 2895-2899 (2008).
22. Shien, K. et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 73, 3051-3061 (2013).
23. Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
24. Kim, E. S. et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discovery 1, 44-53 (2012).
25. Martin, K. H., Slack, J. K., Boerner, S. A., Martin, C. C. & Parsons, J. T. Integrin connections map: To infinity and beyond. Science 296, 1652-1653 (2002).
26. Prior, I. A. & Hancock, J. F. Ras trafficking, localization and compartmentalized signalling. Semin. Cell Devel. Biol. 23, 145-153 (2012).
27. Newlaczyl, A. U. & Yu, L. G. Galectin-3-A jack-of-all-trades in cancer. Cancer Lett. 313, 123-128 (2011).
28. Shalom-Feuerstein, R. et al. K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3. Cancer Res. 68, 6608-6616 (2008).
29. Markowska, A. I., Liu, F. T. & Panjwani, N. Galectin-3 is an important mediator of VEGF-and bFGF-mediated angiogenic response. J. Exp. Med. 207, 1981-1993 (2010).
30. Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761-774 (2011).
31. Bivona, T. G. et al. FAS and NF-KB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471, 523-526 (2011).
32. Chien, Y. et al. RalB GTPase-mediated activation of the IKB family kinase TBK1 couples innate immune signaling to tumour cell survival. Cell 127, 157-170 (2006).
33. Rajasekhar, V. K., Studer, L, Gerald, W., Socci, N. D. & Scher, H. I. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-KB signalling. Nat. Commun. 2, 162 (2011).
34. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
35. Vermeulen, L, de Sousa e Melo, F., Richel, D. J. & Medema, J. P. The developing cancer stem-cell model: Clinical challenges and opportunities. Lancet Oncol. 13, e83-e89 (2012).
36. Medema, J. P. Cancer stem cells: the challenges ahead. Nat. Cell Biol. 15, 338-344 (2013).
37. Li, X. et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Nat. Cancer Institute 100, 672-679 (2008).
38. Xu, L. Cancer stem cell in the progression and therapy of pancreatic cancer. Front. Biosci. (Landmark edition) 18, 795-802 (2013).
39. Zheng, Y. et al. A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumour propagation in NSCLC and requires Notch3 for self-renewal. Cancer Cell 24, 59-74 (2013).
40. Ginestier, C. et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle8, 3297-3302 (2009).
41. Takayama, S. et al. The relationship between bone metastasis from human breast cancer and integrin a(v)[33 expression. Anticancer Res. 25, 79-83 (2005).
42. Asselin-Labat, M. L. et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat. Cell Biol. 9, 201-209 (2007).
43. Umemoto, T. et al. CD61 enriches long-term repopulating hematopoietic stem cells. Biochem. Biophys. Res. Commun. 365, 176-182 (2008).
44. Brooks, P. C, Clark, R. A. & Cheresh, D. A. Requirement of vascular integrin av[33 for angiogenesis. Science 264, 569-571 (1994).
45. Scheppke, L. et al. Notch promotes vascular maturation by inducing integrin-mediated smooth muscle cell adhesion to the endothelial basement membrane. Blood 119, 2149-2158 (2012).
46. Cowden Dahl, K. D., Robertson, S. E., Weaver, V. M. & Simon, M. C. Hypoxia-inducible factor regulates av[33 integrin cell surface expression. Mol. Biol. Cell 16, 1901-1912 (2005).
47. Jinushi, M. et al. ATM-mediated DNA damage signals mediate immune escape through Integrin-av[33-Dependent Mechanisms. Cancer Res. 72, 56-65 (2012).
48. Hamada, J-i. et al. Overexpression of homeobox gene HOXD3 induces coordinate expression of metastasis-related genes in human lung cancer cells. Int. J. Cancer 93, 516-525 (2001).
49. Evellin, S. et al. FOSL1 controls the assembly of endothelial cells into capillary tubes by direct repression of av and [33 integrin transcription. Mol. Cell. Biol. 33, 1198-1209 (2013).
50. Jin, Y. et al. Human integrin [33 gene expression: Evidence for a megakaryocytic cell-specific cis-acting element. Blood 92, 2777-2790 (1998).
51. Rothhammer, T. et al. The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell. Mole. Life Sci. 61, 118-128 (2004).
52. Teicher, B. A. & Chari, R. V. Antibody conjugate therapeutics: Challenges and potential. Clin. Cancer Res. 17, 6389-6397 (2011).
53. Cheresh, D. A. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc. Natl Acad. Sci. USA 84, 6471-6475 (1987).
54. Brooks, P. C. et al. Anti-integrin av[33 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96, 1815-1822 (1995).
55. Bhat, K. P. et al. Mesenchymal differentiation mediated by NF-KB promotes radiation resistance in glioblastoma. Cancer Cell (2013).
56. Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642-655 (2012).
57. Cascone, T. et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J. Clin. Invest. 121, 1313-1328 (2011).
58. Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genetics 44, 852-860 (2012).
59. Mielgo, A. et al. A MEK-independent role for CRAF in mitosis and tumour progression. Nat. Med. 17, 1641-1645 (2011).